Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis

Evaluation of <sup>68</sup>Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617 Therapy: A Radiomics Analysis

<sup>177</sup>Lutetium PSMA-617 (Lu-PSMA) therapy in patients with metastatic castration resistant prostate cancer (mCRPC) has gained visibility through the ongoing phase III trial. The data on prediction of therapy outcome and survival out of pretherapeutic imaging parameters is still s...

Full description

Bibliographic Details
Main Authors: Wolfgang Roll, Philipp Schindler, Max Masthoff, Robert Seifert, Katrin Schlack, Martin Bögemann, Lars Stegger, Matthias Weckesser, Kambiz Rahbar
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
PSMA
PSMA-617
radiomics
radionuclide therapy
mCRPC
Online Access:https://www.mdpi.com/2072-6694/13/15/3849

Internet

https://www.mdpi.com/2072-6694/13/15/3849

Similar Items